Skip to main content
. 2021 Oct 27;12:774026. doi: 10.3389/fimmu.2021.774026

Figure 1.

Figure 1

VSV-MARV vaccination protects NHPs within 7 days from lethal challenge. (A) Survival and (B) clinical score of vaccinated and challenged NHPs are shown. Statistical significance among survival rates was determined using Mantel-Cox test. Levels of (C) platelets, (D) MARV viremia, (E) aspartate aminotransferase (AST) and (F) alkaline phosphatase (ALP) in the blood or serum of MARV-infected NHPs. Mean and standard deviation (SD) are depicted in (C). Statistical significance among groups was determined using two-way ANOVA with Tukey’s multiple comparisons. Statistical significance is indicated as **p < 0.01, and *p < 0.05.